Quick Answer
Ultragenyx Pharmaceutical Inc. reported Stockholders Equity of -$80.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed a decrease of -131.4% in Stockholders Equity from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $165.71 million | Q2 2014: $153.08 million | Q3 2014: $199.33 million | Q1 2015: $341.12 million | Q2 2015: $319.28 million | Q3 2015: $576.76 million | Q1 2016: $489.82 million | Q2 2016: $443.90 million | Q3 2016: $455.89 million | Q1 2017: $488.48 million | Q2 2017: $429.45 million | Q3 2017: $365.56 million | Q1 2018: $723.66 million | Q2 2018: $703.97 million | Q3 2018: $662.60 million | Q1 2019: $886.73 million | Q2 2019: $819.79 million | Q3 2019: $727.27 million | Q1 2020: $609.15 million | Q2 2020: $695.59 million | Q3 2020: $666.19 million | Q1 2021: $1.05 billion | Q2 2021: $972.17 million | Q3 2021: $933.67 million | Q1 2022: $796.42 million | Q2 2022: $678.07 million | Q3 2022: $468.83 million | Q1 2023: $220.48 million | Q2 2023: $129.03 million | Q3 2023: $31.71 million | Q1 2024: $140.26 million | Q2 2024: $432.42 million | Q3 2024: $346.83 million | Q1 2025: $144.25 million | Q2 2025: $151.29 million | Q3 2025: $9.16 million.
- Over the full 15 years of available data (2011 to 2025), Ultragenyx Pharmaceutical Inc.'s Stockholders Equity has declined by 904.9%.
- Historical annual values: Fiscal year 2025: -$80.00 million | Fiscal year 2024: $255.00 million | Fiscal year 2023: $275.00 million | Fiscal year 2022: $352.00 million | Fiscal year 2021: $922.56 million | Fiscal year 2020: $1.15 billion | Fiscal year 2019: $653.76 million | Fiscal year 2018: $608.91 million | Fiscal year 2017: $383.45 million | Fiscal year 2016: $473.97 million | Fiscal year 2015: $531.09 million | Fiscal year 2014: $184.95 million | Fiscal year 2013: -$74.82 million | Fiscal year 2012: -$27.05 million | Fiscal year 2011: -$7.96 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: